Search

everythinglearnresearchcommunity

for

Search:↓

Microneedling can cause sneezing and eye tearing due to nerve stimulation, particularly near the temples and forehead. Some users find it lessens over time, while others prefer using finasteride and minoxidil for hair growth.

A 24-year-old male has been struggling with hair loss since 2020, trying treatments like minoxidil, finasteride, dutasteride, PRP, vitamins, proteins, and exosomes, but hasn't seen significant improvement. He is considering a hair transplant due to the lack of results from these treatments.

A user who didn't respond well to minoxidil and finasteride is considering the role of IGF-1 in hair loss treatment effectiveness. They discuss the potential of using HGH to improve hair growth and other health issues, referencing several sources that suggest IGF-1 levels may influence hair loss and treatment response.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

This post and conversation are about the molecular mechanisms triggered by microneedling, specifically its effects on inflammation, tissue remodeling, epithelial proliferation, differentiation, and collagen synthesis. The discussion highlights the potential benefits of microneedling for hair loss treatment.

The user experienced significant hair regrowth in 5 weeks using Minoxidil, Finasteride, Dutasteride, biotin, collagen, derma stamping, and a mixture of oils, leading others to label them a "hyper responder." Some users advised caution with microneedling frequency to avoid potential scarring.

Hair loss can be influenced by chronic low-level allergies, and treatments like fexofenadine or topical cetirizine may help with regrowth. The user avoids finasteride, dutasteride, and minoxidil, and has tried Regenera Activa and PRF sessions.

The user reports noticeable hair growth after 5 weeks using finasteride, minoxidil, dermarolling, and ketoconazole. They seek confirmation of their progress and question if they are a hyper responder.

The conversation is about someone who initially had positive results with Minoxidil for hair loss, lost those gains due to a hospital stay, and is now not seeing the same results upon resuming treatment. They plan to add microneedling and/or tretinoin to their regimen and are seeking success stories from others who did not respond to Minoxidil alone.

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

The conversation is about finding a solution for scalp inflammation related to AGA, with the user expressing frustration that Minoxidil and Finasteride do not address inflammation. The user has researched glucocorticoids and topical NSAIDs for reducing inflammation and seeks advice from specialists.

A woman is frustrated with her hair loss and the slow, ineffective healthcare system in Canada. She has tried treatments like minoxidil, doxycycline, and kenalog injections, but continues to experience painful inflammation and hair loss.

A 30-year-old is using topical minoxidil 6% and finasteride for hair loss, showing significant progress over five months. They also use dermastamping, nizoral shampoo, and had a hair and scalp treatment.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

A user experienced an allergic reaction, including swollen lymph nodes, to Minoxidil 5% with an aqueous base. Switching to a non-alcohol-based Minoxidil (Prolox 5%) resolved the allergies.

After experiencing hair loss due to alopecia areata following COVID-19 vaccination and infection, the individual saw improvement with steroid treatments and Olumiant. They paused Olumiant during a second COVID-19 infection and expressed concern about potential hair loss flare-ups.

A user shared progress pictures showing significant hair regrowth after using 1mg finasteride and weekly microneedling for about 2.5 to 3 months. The user reported no side effects and maintained good health and mood.

Insulin resistance may increase DHT production, contributing to hair loss, and addressing it through diet, nutrients, and natural DHT blockers like saw palmetto and pumpkin seed oil could help reverse hair loss. Some users prefer medications like finasteride for more effective results.

A user shared their experience with hair loss treatments, including I-PRF injections, mesotherapy, and a topical solution containing Minoxidil and Finasteride. After experiencing side effects, they decided to stop the medicinal treatments and focus on natural alternatives like I-PRF, microneedling, and essential oils.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

The user is experiencing sudden hair loss and is considering micro-needling, low-level light therapy, iron supplements, folihair, and Omega 3. They are hesitant to start finasteride, suspecting the hair loss might be due to telogen effluvium from a past COVID-19 infection.

The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.

The user did not respond to minoxidil and is considering using tretinoin to improve results. They also explored finasteride, microneedling, adapalene, red light therapy, and oral minoxidil as potential treatments.

The conversation discusses alternatives for hair loss treatment for someone allergic to finasteride, suggesting options like hair systems, topical anti-androgens such as CB-03-01, RU58841, and kx-826. It highlights the challenges faced by individuals allergic to anti-androgen inhibitors and the need for more information on this topic.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

The conversation discusses the effectiveness of finasteride and microneedling for treating hair loss. The linked article is seen as an advertisement for these treatments.

The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.